Understanding TZDs and Heart Failure

Why pioglitazone (Actos) is risky for some hearts — and what to use instead

Helps insulin work. Holds onto water. Wrong drug if your heart is already weak.



Online: https://go.riasalimd.com/tzds-guide

Rias KS Ali, MD FACC

Board Certified in Interventional Cardiology & Cardiovascular Disease

4740 Mile Stretch Drive, Holiday FL 34690 | Office: (727) 943-5200 | Fax: (727) 943-5201 | RiasAliMD.com

Last Updated: August 2026

Names & Terms You Will Hear

Term	Meaning
TZDs (thiazolidinediones)	A group of diabetes pills. They help the body use insulin better.
Pioglitazone (Actos)	The TZD most used in the U.S. today.
Rosiglitazone (Avandia)	An older TZD. Rarely used now due to safety worries.
PPAR-gamma agonists	The drug name in science terms. TZDs turn on this switch in fat and muscle cells.
Insulin sensitizer	In plain words: it makes your body respond better to its own insulin.
Fluid-holding diabetes drug	TZDs make the body hold onto salt and water. That is the main side effect.
PPAR-gamma (formal name)	The receptor name. Same drugs. Same target.

What Is TZDs and Heart Failure?

- TZDs help your body use its own insulin better. They work in fat and muscle cells. They tell those cells to take in sugar from the blood.
- Pioglitazone is the TZD still in use. Rosiglitazone (Avandia) is mostly gone due to safety worries.
- TZDs make the kidneys hold onto extra salt and water. Blood volume rises about 6-7%. That extra fluid is the main cause of heart failure side effects.
- TZDs are NOT the first choice for diabetes today. They sit behind metformin, SGLT2 inhibitors, and GLP-1 agonists.
- TZDs can help fatty liver disease (NAFLD) and some types of insulin resistance. Those are their best uses today.

Why It Matters

- Pioglitazone roughly doubles the risk of being put in the hospital for heart failure. (About 5-6% vs 4% over several years.)
- The risk is highest in the first 30 days after starting or raising the dose. That is when patients watch the least.
- Newer drugs (SGLT2 inhibitors, GLP-1 agonists) LOWER heart failure risk while still treating diabetes. If you have heart disease, picking a TZD is rarely the right call.
- If you already have heart failure, pioglitazone is not safe in NYHA class III-IV. It is also not advised in class I-II. The extra fluid can push a weak heart into the hospital within weeks.
- There is a small but real bladder cancer signal with long use (over 2 years). Patients with a past bladder cancer should not use pioglitazone.

Treatment Options

- If you already have heart failure: stop pioglitazone. Switch to an SGLT2 inhibitor (empagliflozin or dapagliflozin). These treat both diabetes AND heart failure.
- If you have heart disease but no heart failure: SGLT2 inhibitors or GLP-1 agonists (semaglutide, dulaglutide) are the better pick. They lower heart events and slow kidney disease.
- If you have only diabetes and no heart issues: metformin is still first choice. Pioglitazone is OK as an add-on when other drugs do not fit.
- If you have fatty liver (NAFLD or NASH) with insulin resistance: pioglitazone has the best fatty-liver data. Weigh this against the fluid risk.
- Do not mix pioglitazone with insulin if you have heart disease. The fluid risk goes up a lot.
- Daily weights at home. Same scale. Same time. Same clothes. A 3-5 lb jump over a few days is the first warning sign.
- If pioglitazone is the right pill for you, start at 15mg daily. Stay there for the first 4-6 weeks. This limits the fluid peak.



What to check for at home: press a finger into the front of the shin or ankle for a few seconds. Left: before pressing. Right: pressing shows the dent (pitting) that is the hallmark of fluid retention — the same fluid buildup pioglitazone can cause. New or worsening pitting, together with a fast weight gain, is a reason to call us. (This photo is a general demonstration of the pitting-edema test, not a pioglitazone case.) Image: James Heilman, MD, Wikimedia Commons (CC BY-SA 3.0).

Risks, Benefits, and Alternatives

Every choice has trade-offs. Use this table to start the shared decision conversation.

Option	Risks	Benefits	Alternatives
Pioglitazone (TZD)	Doubles heart failure hospital risk. Weight gain (5-10 lb is typical). Bone fracture risk (women). Bladder cancer signal with long use. Macular edema (rare).	Helps insulin work. Holds LDL steady. Raises HDL. Lowers triglycerides. Best diabetes pill for fatty liver. Lowers heart events in some groups.	SGLT2 inhibitor (better if you have any heart, kidney, or HF issue). GLP-1 agonist (better if weight loss is also a goal). Metformin (first choice).
SGLT2 inhibitor (empagliflozin, dapagliflozin)	Yeast infections (more in women). Urinary infections. Mild dehydration. Rare diabetic ketoacidosis if insulin is very low.	Cuts HF hospital risk by about 30%. Lowers heart death. Slows kidney disease. Mild weight loss (about 5 lb).	GLP-1 agonist. Pioglitazone (only if heart is healthy). Insulin.
GLP-1 receptor agonist (semaglutide, dulaglutide)	Nausea and vomiting (most settle in 4-6 weeks). Gallstone risk. Rare pancreatitis. A shot, most often weekly.	Big weight loss (10-15% of body weight). Cuts heart events by 15-20%. Safe for heart failure or even helpful.	SGLT2 inhibitor (a pill, cheaper). Pioglitazone.
Stay on pioglitazone with active heart disease	Heart failure events go up. May lead to hospital stays or worse over 1-3 years.	Avoids the work of a drug change. Keeps current sugar control.	A class switch is almost always better when heart disease is in the picture.

Common Misconceptions

Myth	Reality
If a diabetes pill controls my sugar well, it must be good for my heart.	Not always. Pioglitazone lowers A1c well, but it can double the heart failure risk. Newer drugs (SGLT2i, GLP-1) lower BOTH sugar and heart events. That is today's standard.
Pioglitazone always causes heart attacks.	It does not. Pioglitazone actually CUTS heart attacks in some trials (PROactive, IRIS). The issue is heart FAILURE. That is a different problem: too much fluid, not blocked arteries.
If I have not had heart failure, pioglitazone is safe for me.	Less risky, but not zero. The first 30 days after starting are the worst. Watch your weight and ankle swelling. Watch more closely if you are over 65 or have high blood pressure.
The bladder cancer risk means I should never take pioglitazone.	The real risk is small (about 1 extra case per 1,500 patients over 5 years). For most people, the sugar benefit is worth it. Avoid only if you have a past bladder cancer or active bladder disease.
I can stop pioglitazone all at once if I gain weight.	You can stop without tapering, but tell us first. We will start a new drug the same day. That keeps your sugar from running high.
Pioglitazone is the same as metformin.	Different drugs. Metformin cuts sugar made by the liver. Pioglitazone helps muscle and fat cells respond to insulin. They are sometimes used together.
If my doctor put me on pioglitazone, I should not ask about it.	Always ask. Especially if no one told you about heart failure warning signs, or you got heart disease while on it. Drug choices age. What was right 5 years ago may not be right today.

Possible Complications

Knowing what can go wrong helps you spot problems early. Most complications are uncommon, especially with treatment.

Where / What	What Can Happen
Heart failure hospitalization	The most important side effect. About 5-6% of pioglitazone users vs 4% on placebo over several years. Higher in the first 30 days, in older patients, and when mixed with insulin.
Weight gain	Usually 5-10 lb in the first year. A mix of fluid and true fat. Diet and exercise can offset some of it.
Bone fractures	A small rise in arm and leg fractures. Mostly in women past menopause. About 1 extra fracture per 100 women treated for 5 years.
Bladder cancer	A small but real signal with a total dose over 28,000mg (about 3 years at 30mg/day). The risk levels off after stopping the drug.
Macular edema	Rare swelling in the back of the eye. Causes blurry vision. Usually goes away after stopping pioglitazone.
Low blood sugar (when mixed with insulin or a sulfonylurea)	Pioglitazone alone rarely causes low sugar. But it raises the risk when stacked on insulin or a sulfonylurea.

4740 Mile Stretch Drive, Holiday FL 34690 | Office: (727) 943-5200 | Fax: (727) 943-5201 | RiasAliMD.com

Points to Know

If you remember nothing else, remember these key points.

- Daily weights. Same time. Same clothes. Same scale. A 3-5 lb jump over a few days is your first warning.
- Watch for new ankle swelling. Especially if it leaves a dent when you press it.
- Hard time breathing when lying flat is a key sign of heart failure. It can wake you at night. Call us.
- Bring all your pill bottles to every visit. Pioglitazone interacts with some HIV drugs, gemfibrozil, and some antifungals.
- Yearly bone scan if you are female and over 60 on pioglitazone. There is a small fracture risk.
- Eye exam every year. Pioglitazone can rarely cause swelling in the back of the eye (blurry vision).
- Do not mix pioglitazone with high-dose insulin if you have heart disease. The fluid risk goes way up.
- If you get new heart disease or heart failure while on pioglitazone, call us to switch classes.

When to Call Us - and When to Call 911

If you are not sure, call. We would rather hear from you twice than miss a real problem.

- **Call us today** for sudden weight gain of 3-5 lb in a few days.
- **Call us this week** for new or worse leg or ankle swelling.
- **Call 911** for bad trouble breathing. **Call us today** for milder trouble breathing when lying down or with light activity.
- **Call us right away** if you wake at night gasping for breath.
- **Call us** for new bad tiredness or weakness.
- **Call us right away** for blood in urine, or pain or burning when you pee. We will check for a UTI and rule out bladder cancer.
- **Call us today** for new blurry or distorted vision.
- **Call us** before any surgery, CT contrast scan, or dental procedure. We will adjust your diabetes plan.

Office: (727) 943-5200

Trusted Resources

The links below are the trusted resources Dr. Ali used to write this guide and that he recommends you visit for more information. Each is a clickable link in the digital version and a Short.io tracked URL on the printed version.

- Cleveland Clinic — Pioglitazone (Actos) - Patient drug profile including dosing and side effects.
- American Heart Association — Diabetes & Heart Disease - AHA patient education on diabetes-heart connections.
- American Diabetes Association — Standards of Care - ADA's 2024 Standards of Medical Care — the authoritative diabetes guideline.
- MedlinePlus — Pioglitazone - NIH-curated drug information.

Sources Used to Build This Guide

Every recommendation in this guide is grounded in one or more of the studies, guidelines, or trusted resources below. Short links are tracked so Dr. Ali can see which references patients are reading; nothing personally identifying is captured.

- PROactive Trial — Pioglitazone in macrovascular disease (Dormandy et al, Lancet 2005) *[Clinical Trial]*
  Landmark RCT: pioglitazone reduces composite MACE but doubles heart failure hospitalization. Frames the central RBA tradeoff.
- IRIS Trial — Pioglitazone after stroke or TIA (Kernan et al, NEJM 2016) *[Clinical Trial]*
  Pioglitazone cuts stroke/MI by 24% in insulin-resistant non-diabetic stroke patients — but again raises HF and fracture risk. Key benefit-risk data.
- FDA Drug Safety Communication — Pioglitazone and bladder cancer (FDA 2016) *[Guideline]*
  FDA position on bladder-cancer signal: small but real, dose- and duration-dependent. Anchors the misconceptions section.
- AHA Scientific Statement — Thiazolidinediones and CV Disease (Circulation 2003) *[Guideline]*
  AHA position: avoid TZDs in NYHA III-IV heart failure. Establishes the explicit contraindication.
- ADA/EASD 2022 Consensus Report — Management of Hyperglycemia in T2D *[Guideline]*
  Current diabetes-management algorithm: SGLT2i and GLP-1 RAs are preferred when cardiovascular disease or HF is present. TZDs are alternatives, not first-line.
- EMPA-REG OUTCOME — Empagliflozin cardiovascular outcomes (Zinman et al, NEJM 2015) *[Clinical Trial]*
  Anchors the SGLT2 inhibitor alternative: 35% reduction in HF hospitalization. The 'opposite story' from TZDs.
- DAPA-HF — Dapagliflozin in Heart Failure (McMurray et al, NEJM 2019) *[Clinical Trial]*
  Confirms SGLT2 inhibitor benefit in HF regardless of diabetes status. Why we prefer SGLT2i over TZD when HF is on the table.
- Cleveland Clinic — Pioglitazone (Actos) *[Clinical]*
  Patient-friendly drug profile with dosing, monitoring, and warning signs.

About This Guide

Rias KS Ali, MD FACC | Board Certified in Interventional Cardiology & Cardiovascular Disease

4740 Mile Stretch Drive, Holiday FL 34690 | Office: (727) 943-5200 | Fax: (727) 943-5201 | RiasAliMD.com

Version: 2026-08-15

Reviewer note: Reviewed against ADA 2022, AHA, and Cleveland Clinic drug-class pages. Ours adds: explicit comparison chart of HF hospitalization risk by drug class, the PROactive/IRIS trial signal (cardiovascular benefit AND HF doubling), FDA bladder-cancer position, and the modern preference for SGLT2i / GLP-1 alternatives in any patient with CV disease.

Disclaimer

This guide is for educational purposes only and does not replace medical advice from your physician. Recommendations may not apply to every patient. Always follow the specific instructions of Dr. Ali and your care team. In an emergency call 911 or go to the nearest emergency department.

Take This Guide With You

Scan or visit: https://go.riasalimd.com/tzds-guide

Online: https://go.riasalimd.com/tzds-guide

Office: (727) 943-5200

4740 Mile Stretch Drive, Holiday FL 34690 | Office: (727) 943-5200 | Fax: (727) 943-5201 | RiasAliMD.com